2-Bromo-3-chloro-pentan | 60053-32-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氯化物
• 英文名称: 2-Bromo-3-chloro-pentan
• 英文别名: 3-bromo-3-chloro-pentane；3-Brom-3-chlor-pentan；3-Bromo-3-chloropentane
• CAS: 60053-32-9
• 化学式: C₅H₁₀BrCl
• 分子量: 185.491
• InChiKey: DNDJLHOJWIMPHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  7
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  N,N-diethyl chloroacetamide 在 sodium hypobromide 作用下， 生成 2-Bromo-3-chloro-pentan
  参考文献：
  名称：

  gem-Dihalides from the Hofmann Degradation of α-Haloamides¹

  摘要：

  DOI：

  10.1021/ja01591a064

文献信息

• [EN] KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KYNURÉNINE-3-MONOOXYGÉNASE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS
  申请人：CHDI FOUNDATION INC

  公开号：WO2015047982A2

  公开（公告）日：2015-04-02

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
• gem-Dihalides from the Hofmann Degradation of α-Haloamides¹
  作者：Calvin L. Stevens、Tapan K. Mukherjee、Vincent J. Traynelis

  DOI：10.1021/ja01591a064

  日期：1956.5